A Long-term Follow up Study of EXG102-031 in Participants With wAMD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

42 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-03-13

Study Completion Date

2030-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD. Patients will complete visits from the parent study, and then into this long-term follow-up study for continuous safety monitoring for up to 5 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of EXG102-031 in Participants With wAMD

NCT06183814

Neovascular Age-related Macular Degeneration

RECRUITING PHASE1/PHASE2

A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)

NCT06817343

Neovascular Age-Related Macular Degeneration (nAMD) Neovascular (Wet) Age-related Macular Degeneration (AMD)

ENROLLING_BY_INVITATION PHASE1

A Study of EXG102-031 in Patients With wAMD (Everest)

NCT05903794

Neovascular (Wet) Age-related Macular Degeneration (nAMD)

ACTIVE_NOT_RECRUITING PHASE1

To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)

NCT06888492

NOT_YET_RECRUITING EARLY_PHASE1

A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration

NCT03387566

Neovascular Age-Related Macular Degeneration

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will enroll patients with wet age-related macular degeneration (wAMD) who have previously be treated with EXG102-031 injection, those patients will Voluntary join this long-term follow-up study to be evaluated the long-term safety and efficacy.

The first two years of long-term follow-up will be conducted every 2 months; From 3 years to 5 years after administration,follow-up visits will be conducted every six months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Wet Age-related Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention, only for observational studies

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Previously received treatment with EXG102-031 in the study (EXG102-031-111);
2. Paticipantes are informed consent and willingness to follow protocol procedures.